Beta blocker specificity: A building block toward personalized medicine

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 86-89

  DeGeorge Jr , Brent R ^a   Koch, Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG CONFORMATION; GENETIC HETEROGENEITY; GENOTYPE; HEART FAILURE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; DRUG DESIGN; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 33846001299     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30476     Document Type: Review

References (18)

1. Lee, T.H. 2001. Management of heart failure: AHA/ACC guidelines summary. Heart disease: a textbook of cardiovascular medicine. 6th edition. E. Braunwald, editor. 101:652-685.
2. Becker, O.M., et al. 2004. G-protein coupled receptors: in silico drug discovery in 3D. Proc. Natl. Acad. Sci. U. S. A. 101:11304-11309.
3. Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. 2002. Seven-transmembrane- spanning receptors and heart function. Nature. 415:206-212.
4. 1-adrenoreceptor: identification and rapid screening assay [research letter]. Lancet. 353:897.
5. 1 adrenergic receptor is associated with resting heart rate. Am. J. Hum. Genet. 70:935-942.
6. Small, K.M., McGraw, D.W., and Liggett, S.B. 2003. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43:381-411.
7. 1-adrenergic receptor. J. Biol. Chem. 274:12670-12674.
8. 1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am. J. Physiol. Heart Circ. Physiol. 290: H1427-H1432.
9. Brauwald, E., and Bristow, M.R. 2002. Congestive heart failure: fifty years of progress. Circulation. 102(20 Suppl. 4):IV14-IV23.
10. Beta-blocker Evaluation of Survival Trial Investigators. 2001. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344:1659-1667.
11. Leinweber, K. 2004. Beta-adrenergic receptor polymorphism in human cardiovascular disease. Ann. Med. 36:64-69.
12. Giempmans, B.N., Adams, S.R., Ellisman, M.H., and Tsien, R.Y. 2006. The fluorescent toolbox for assessing protein localization and function. Science. 312:217-224.
13. Miyawaki, A. 2003. Visualization of the spatial and temporal dynamics of intracellular signaling. Dev. Cell. 4:295-305.
14. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117:229-235. doi:10.1172/JCI30012.
15. Yancy, C.W., et al. 2001. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. 344:1358-1364.
16. Bond, R.A., and Ijzerman, A.P. 2006. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27:92-96.
17. 2c- adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347:1135-1142.
18. Zineh, I., and Johnson, J.A. 2006. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert opin. Pharmacother. 11:1417-1427.